肾细胞癌抗凋亡基因bcl-2的免疫组化研究  

Immunohistochemical study of apoptosis suppressing oncoprotein bcl 2 in human renal cell carcinoma

作　　者：邹高德[1,2] 葛根[1,2] 孙锡林[1,2] 庄文华[1,2] 吴绮明[1,2] 张文昌[1,2] 

机构地区：[1]江西医学院第二附属医院泌尿外科 [2]江西医学院病理教研室

出　　处：《中华泌尿外科杂志》1997年第6期329-331,共3页Chinese Journal of Urology

摘　　要：为探讨ｂｃｌ２基因产物表达与肾癌生物学行为及预后的关系，采用免疫组化ＬＳＡＢ法对６０例肾细胞癌和５例正常肾组织ｂｃｌ２表达产物进行检测。结果表明：６６．７％肾癌显示阳性，正常肾组织均为阴性反应。ｂｃｌ２表达与肾癌的分期分级有关，且随着肾癌分期、分级的上升而降低（Ｐ＜０．０１）；ｂｃｌ２表达与肾癌组织学类型无关；ｂｃｌ２阳性表达者预后较好。提示ｂｃｌ２可作为肾癌恶性程度及预后的估价性指标。renal cell carcinomas(RCC)and 5 normal renal tissue specimens have been studied by LSAB immunohistochemical methods,using bcl 2 antibody to find the correlation between bcl 2 and the biological behaviors and prognosis of RCC.Positive staining of bcl 2 protein was found in 66.7% of RCC(40/60),but none in normal renal tissues.Expression of bcl 2 was closely related to the clinical stage and tumor grade, the incidence of expression of bcl 2 gene being decreased with stage and grading ( P <0.01).No correlation was found between bcl 2 expression and the histologic type.Cases with negative bcl 2 expression had poor prognosis.bcl 2 might be applicable as a tumor marker for the evaluation of maligant potential and prognosis of RCC.

关 键 词：肾肿瘤 癌 基因 BCL-2 免疫组织化学 

分 类 号：R737.110.3[医药卫生—肿瘤]